The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as ‘a highly significant milestone’ in the company’s development.
he Redx Pharma
group is focused on early stage drug discovery and development programmes at sites in Liverpool
(Redx Oncology) and at Alderley Park
, Cheshire (Redx Anti-infectives).
ierre Fabre, the second largest French pharmaceutical company, enjoys world-class expertise in both oncology and dermatology.
Its portfolio is focused on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas.
The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.
Neil Murray, chief executive, Redx Pharma said: “We are delighted to have reached an agreement with Pierre Fabre, which represents the first major transaction for our anti-cancer subsidiary Redx Oncology. The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits. We look forward to benefitting from Pierre Fabre’s outstanding capabilities in this area and developing a long and successful partnership.” Christian Bailly, Head of Research at Pierre Fabre Pharmaceuticals, said: “We are looking forward to working with Redx Pharma as part of our commitment to external innovation to complete our cutting-edge R&D capabilities.
ruce Murray, Managing Director of Moletest, explained, “ComplianceControl Centre offers the ideal software for Moletest in ensuring we are compliant with the industry regulations, and are audit ready, at all times.
It places Europe at the forefront of collaborative research between industry and academia for health challenges.Redx Pharma CEO, Dr Neil Murray, said: “Redx Pharma is one of the UK’s leading biotech companies in the fight against AMR, so it was important for us to be involved in this consortium. IMI is an initiative which provides a pivotal platform for industry and academia to join forces and develop and pursue innovative ways of tackling this critical issue.“Gram-negative infections like e-coli are amongst the toughest to deal with and represent a grave threat to human health world-wide.
r Neil Murray chief executive of Redx Pharma the largest UK biotech working on the development of new antibiotics has stated “We are at the tipping point where some 70% of known bacteria have developed resistance to one or more antibiotics.
Dr Neil Murray, chief executive of Redx Pharma, said: “Our business is at the cutting edge of early stage drug development and, working with our colleagues at the Royal, we are delighted to be now in the vanguard of NHS England’s strategy of fostering closer working ties with industry.
I hope this strategy inspires discussion of new concepts around this agenda to enable commercial companies to fully engage on this vital challenge for society."Dr Neil Murray, CEO of Redx Pharma, commented "Every year some 25,000 people in the EU die as a result of a serious drug resistant infection - mostly acquired in healthcare settings.